Amphastar Pharmaceuticals Files 8-K on Financials

Ticker: AMPH · Form: 8-K · Filed: 2024-11-06T00:00:00.000Z

Sentiment: neutral

Topics: financial-reporting, sec-filing

Related Tickers: AMPH

TL;DR

AMPH filed an 8-K on Nov 6th for financial updates. Details to follow.

AI Summary

Amphastar Pharmaceuticals, Inc. filed an 8-K on November 6, 2024, to report on its results of operations and financial condition, as well as to file financial statements and exhibits. The filing does not contain specific financial figures or operational details within the provided text, but serves as a notification of these items.

Why It Matters

This 8-K filing indicates that Amphastar Pharmaceuticals is providing updates on its financial performance and condition, which is crucial information for investors to assess the company's health.

Risk Assessment

Risk Level: low — The filing is a standard procedural disclosure and does not contain any negative news or significant events.

Key Players & Entities

FAQ

What specific financial results or conditions are being reported by Amphastar Pharmaceuticals in this 8-K?

The provided text of the 8-K filing does not specify the details of the results of operations or financial condition being reported, only that the filing is made for this purpose.

When was this 8-K filing submitted to the SEC?

The 8-K filing was submitted on November 6, 2024.

What is the primary purpose of this 8-K filing for Amphastar Pharmaceuticals?

The primary purpose is to report on the company's results of operations and financial condition, and to file financial statements and exhibits.

Where are Amphastar Pharmaceuticals' principal executive offices located?

Amphastar Pharmaceuticals' principal executive offices are located at 11570 6th Street, Rancho Cucamonga, California 91730.

Does this filing indicate any specific events or changes that have occurred?

This filing indicates that Amphastar Pharmaceuticals is reporting on its results of operations and financial condition, and filing financial statements and exhibits, but does not detail specific events within the provided text.

Filing Stats: 505 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2024-11-06 16:31:09

Key Financial Figures

Filing Documents

02. Results of Operations and Financial Condition

Item 2.02. Results of Operations and Financial Condition. On November 6, 2024, Amphastar Pharmaceuticals, Inc. issued a press release announcing its financial results for the three months ended September 30, 2024. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits: Exhibit No. Description 99.1 Press release, dated November 6, 2024, issued by Amphastar Pharmaceuticals, Inc. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: November 6, 2024 Amphastar Pharmaceuticals, Inc. By: /s/ WILLIAM J. PETERS William J. Peters Chief Financial Officer, Executive Vice President and Treasurer

View on Read The Filing